Table 4.

Examples of FDA-approved indications for commonly used anti-TNF drugs in managing immune-related conditions [230]

Drug	Indications	Structure and target
Infliximab	Ankylosing spondylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis	Chimeric monoclonal antibody against TNF-α
Etanercept	Ankylosing spondylitis, psoriasis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis	A dimeric fusion protein of TNFR2 and a human IgG1 Fc domain
Adalimumab	Ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and uveitis	Fully humanized monoclonal antibody against TNF-α
Golimumab	Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis	Fully humanized monoclonal antibody against TNF-α
Certolizumab pegol	Ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, rheumatoid arthritis	Fully humanized PEGylated anti-TNF-α monoclonal antibody